AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
rimantadine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| adamantane derivatives | 2383 | 13392-28-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 20 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 15.93 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AKT2,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,EIF2AK3,EPHB4,ERBB2,GRK2,IRAK4,ITK,JAK3,MAP2K6,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MET,NTRK2,PDK2,PDK4,PIM2,PRKDC,TEK,TGFBR1 | 29 | |||
| kinase-selectivity-class | EIF2AK3 | 1 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 17, 1993 | FDA | CARACO |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J05AC02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Cyclic amines |
| FDA MoA | N0000175542 | M2 Protein Inhibitors |
| FDA EPC | N0000175543 | Influenza A M2 Protein Inhibitor |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D019384 | Nucleic Acid Synthesis Inhibitors |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
Related Drugs by ATC class:
J05AC Cyclic amines 1 drug
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Influenza due to Influenza A virus | indication | 442438000 | |
| Influenza A Prevention | indication | ||
| Acute nephropathy | contraindication | 58574008 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Seizure disorder | contraindication | 128613002 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.41 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Solute carrier family 22 member 2 | Transporter | IC50 | 5.36 | CHEMBL | |||||
| Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 5.14 | CHEMBL | |||||
| Matrix protein 2 | Ion channel | INHIBITOR | CHEMBL | CHEMBL | |||||
| Polymerase acidic protein | Enzyme | IC50 | 4.96 | CHEMBL | |||||
| Matrix protein 2 | Ion channel | Kd | 7.80 | CHEMBL | |||||
| Matrix protein 2 | Ion channel | Kd | 6.29 | CHEMBL | |||||
| Matrix protein 2 | Ion channel | WOMBAT-PK | |||||||
| Matrix protein 2 | Ion channel | Kd | 7.80 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4023897 | VUID |
| N0000021902 | NUI |
| D00901 | KEGG_DRUG |
| 1501-84-4 | SECONDARY_CAS_RN |
| 4020839 | VANDF |
| 4023897 | VANDF |
| C0035629 | UMLSCUI |
| CHEBI:49886 | CHEBI |
| RIM | PDB_CHEM_ID |
| CHEMBL959 | ChEMBL_ID |
| DB00478 | DRUGBANK_ID |
| CHEMBL535396 | ChEMBL_ID |
| D012299 | MESH_DESCRIPTOR_UI |
| 5071 | PUBCHEM_CID |
| 2292 | INN_ID |
| 0T2EF4JQTU | UNII |
| 82093 | RXNORM |
| 42407 | MMSL |
| 5426 | MMSL |
| d03158 | MMSL |
| 004382 | NDDF |
| 004383 | NDDF |
| 108712009 | SNOMEDCT_US |
| 108713004 | SNOMEDCT_US |
| 372532009 | SNOMEDCT_US |
| 0T2EF4JQTU | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Rimantadine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1911 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 21 sections |
| Rimantadine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-202 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 24 sections |
| Rimantadine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52959-305 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 24 sections |
| Rimantadine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-2103 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 24 sections |